Can probiotics improve A1c, plus more?
Probiotics For Diabetes Type 2 diabetes mellitus is a chronic disease caused by insulin resistance and a decrease in peripheral glucose uptake later in life. Obesity, lifestyle, and unhealthy behavior are the most common T2DM risk factors. It is estimated that the prevalence of diabetes in 2010 was 4% and an estimated 5.4% in 2025.
The problem of achieving T2DM is expected to double in the near future. T2DM causes serious complications such as nervous system disorders, kidney disease, and eye problems; Prevention and treatment should, therefore, be considered a priority. For centuries, one of the most effective ways to maintain the balance of intestinal microbiota is the use of probiotics, which are defined as living microorganisms that, when administered in sufficient quantities, provide a health benefit to the host.
Products containing probiotic bacteria have been increasingly preventing or treating a variety of disorders such as irritable bowel syndrome, inflammatory bowel disease and chronic idiopathic constipation, obesity, allergies and respiratory diseases, and various types of diarrhea. It has been suggested that probiotics can positively affect metabolic disorders.
There is some evidence that probiotic intake or supplementation may lower serum cholesterol and increase insulin sensitivity. Several studies have evaluated the beneficial health effects of probiotic dairy products.
The purpose of this study was to evaluate probiotics for diabetes management: the ability of probiotics to alter the metabolic risk factors in type 2 diabetes. It was performed according to PRISMA guidelines. Randomized controlled trials are used in adults with T2DM. The desired result is fasting plasma glucose (FPG), insulin concentrations, insulin resistance was estimated as the homeostatic model score, HbA1c, total cholesterol 9TC) using high-density lipoprotein (HDL) and C-reactive protein (CRP).
These endpoints are taken from research and collected into computer tables. Statistical analysis was performed with Statistica Version 8 RCTs at 10. A total of 38 subjects met inclusion criteria and entered the meta-analysis. 5 out of 6 RCTs showed a significant decrease in FPG after probiotic use, whereas only 1 failed (I 2 = 97.66%; P <0.001).
HbA1c showed reduced rates after receiving probiotics compared to placebo (I 2 = 68.44%, P + 0.0421). Also, there was a decrease in insulin levels on probiotic consumption, but no significant difference in mean insulin levels was observed between users of probiotics and placebo (I 2 = 96.49%; P <0.001). Cholesterol, low-density lipoprotein cholesterol, and CRP did not show any significant change in probiotic consumption. However, triglycerides and high-density lipoprotein cholesterol show positive changes in probiotic intake
Some limitations of this study are the fact that the number of identified RCTs that meet the inclusion criteria is relatively low, and this makes expansion arrangements difficult to assess the effects of particular probiotic strains. In summary, existing RCT meta-analyses show that probiotic supplementation in patients with T2DM has positive effects on selected cardiovascular metabolic parameters. However, a well-designed study is better at understanding the true relationship between probiotic supplementation and modified cardiovascular risk factors before it is recommended as a supportive treatment for T2DM.
Another parallel-group clinical study was conducted to determine the effect of C. ficifolia and/or the use of probiotic yogurt on glycemic control, lipid profile and inflammatory markers in T2DM patients. Eligible criteria are between 25 and 75 years, fasting blood sugar (FBS) of more than 126 mg/dl and controlled lipids without changing the instructions. Participants receive one of four meals lasting 8 weeks. Such interventions include 1) C. ficifolia (100 g); 2) yogurt probiotics (150 g); 3) yogurt Ficifolia and probiotics (100 g C Ficifolia plus 150 g yogurt); and 4) control (diet suggestions). C. Ficifolia and yogurt are consumed at lunchtime and patients are asked not to change their eating habits.
Blood samples were obtained at baseline and at the end of the study. ANOVA and chi-square were used for their statistical analysis of 80 subjects who completed the study. There was no significant change in TC and LDL-C in the control group, but TG increased (P = 0.012) and HDL-C decreased significantly (P = 0.034). All interventions, however, lowered FBS (P = 0.001 in the flask, P = 0.014 in yogurt and P <0.001 in C. Ficifolia and yogurt) and HbA1c (P <0.001 in Ficifolia C, P = 0.002 in yogurt, P = 0.000 in C ficifolia plus yoghurt) compared to the control group (between P groups, 0.001 and <0.001, respectively).
In conclusion, probiotic yogurt and C. ficifolia, alone or in concert, have beneficial effects on lipid profile, glycemic control, inflammation and blood pressure in patients with T2DM.
Probiotics play an important role in our health.
Probiotics are living microorganisms that, when administered in sufficient quantities, confer a health benefit on the host.
Probiotic supplementation has beneficial effects on selected cardiovascular metabolism parameters in patients with T2D.